Patents Examined by Karen A. LaCourciere
  • Stem cell factor formulations and methods
    Patent number: 6288030
    Abstract: The present invention relates to lyophilized formulations of Stem Cell Factor (SCF) with increased stability. The formulations of lyophilized SCF include amino acid buffers and sucrose. Methods of producing said formulations are also disclosed in the specification.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: September 11, 2001
    Assignee: Amgen Inc.
    Inventor: Susan I. Hershenson
  • Antisense inhibition of MADH6 expression
    Patent number: 6277636
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MADH6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MADH6. Methods of using these compounds for modulation of MADH6 expression and for treatment of diseases associated with expression of MADH6 are provided.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: August 21, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of C/EBP beta expression
    Patent number: 6271030
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP beta. Methods of using these compounds for modulation of C/EBP beta expression and for treatment of diseases associated with expression of C/EBP beta are provided.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Jacqueline Wyatt
  • Methods of inhibiting phagocytosis
    Patent number: 6242427
    Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: June 5, 2001
    Assignee: University of Pennsylvania
    Inventors: Alan D. Schreiber, Jong-Gu Park
  • Double targeted gene replacement in unicellular diploid organisms
    Patent number: 6228649
    Abstract: Homozygous gene replacement can be created in unicellular diploid organisms by individually targeting each allele of a gene with genetic constructs containing two different and independent selectable markers. Selection for both markers indicates replacement of both alleles of the gene, or portion thereof. The method can be used to study gene function in these organisms and to create mutant organisms such as attenuated strains of parasitic protozoans for use in live vaccines.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: May 8, 2001
    Assignee: President and Fellows of Harvard College
    Inventors: Stephen M. Beverley, Angela K. Cruz
  • In vivo assay for intravasation
    Patent number: 6228345
    Abstract: The present invention relates to a novel in vivo assay for quantitating intravasation of cancer cells based on a highly sensitive polymerase chain reaction (PCR) utilized in combination with a chick embryo chorioallantoic membrane (CAM) assay. The assay of the invention provides a method for measuring the metastatic potential of cancer cells. The assay also provides a drug screening assay for identification of agents having anti-metastatic activity.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: May 8, 2001
    Assignee: Mount Sinai School of Medicine of New York University
    Inventor: Liliana Ossowski
  • Peptides and compositions which modulate apoptosis
    Patent number: 6221615
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain”, which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: April 24, 2001
    Assignee: Apoptosis Technology, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Antisense inhibition of Fas mediated signaling
    Patent number: 6204055
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: March 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Eric G. Marcusson
  • Nucleic acid-containing composition, preparation and use thereof
    Patent number: 6200956
    Abstract: Pharmaceutical composition useful for transfecting a nucleic acid and characterised in that it contains, in addition to the nucleic acid, at least one transfecting agent and a compound causing the condensation of the nucleic acid, wherein the compound is totally or partly derived from a histone, a nucleoline, a protamine and/or a derivative thereof. The use of the composition for transferring nucleic acids in vitro, ex vivo and/or in vivo is also described.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: March 13, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Scherman, Gérardo Byk, Bertrand Schwartz
  • Antisense inhibition of protein kinase C-theta expression
    Patent number: 6190869
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein kinase C-theta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein kinase C-theta. Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense inhibition of e2f transcription factor 1 expression
    Patent number: 6187587
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Vickie L. Brown-Driver, Lex M. Cowsert
  • Deoxyribonuclease II proteins and cDNAS
    Patent number: 6184034
    Abstract: The present invention provides cDNAs encoding deoxyribonuclease II and isolated, purified deoxyribonuclease II proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II activity and apoptosis are described.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: February 6, 2001
    Assignee: Trustees of Dartmouth College
    Inventors: Alan Eastman, Ronald Krieser
  • Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
    Patent number: 6180403
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr;-converting enzyme (TACE). Antisense oligonucleotides targeted to nucleic acids encoding TACE are preferred. Methods of using these oligonucleotides for inhibition of TACE expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TACE or TNF-&agr; are provided.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: January 30, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Shin Cheng Flournoy, C. Frank Bennett
  • Deoxynucleic alkyl thiourea compounds and uses thereof
    Patent number: 6169176
    Abstract: The invention provides novel deoxynucleic alkyl thiourea (dNXt) oligonucleotide compounds for use in antisense or antigene therapy.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: January 2, 2001
    Assignee: The Regents of the University of California
    Inventors: Thomas C. Bruice, Arya P. Dev
  • Antisense inhibition of E2F transcription factor 3 expression
    Patent number: 6165791
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense inhibition of SRC-3 expression
    Patent number: 6156571
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-3. Methods of using these compounds for modulation of SRC-3 expression and for treatment of diseases associated with expression of SRC-3 are provided.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: December 5, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Tat-SF: cofactor for stimulation of transcriptional elongation by HIV-1 Tat
    Patent number: 6150515
    Abstract: The invention pertains to a novel transcriptional activity factor, Tat-Stimulatory Factor, as well as genes encoding this factor and fragments and biologically functional variants thereof. The Tat-Stimulatory Factor is involved in the regulation of transcriptional elongation of HIV-1 by Tat. The invention also pertains to therapeutics involving the foregoing proteins and genes, and agents that bind to the foregoing proteins and genes.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: November 21, 2000
    Assignee: Massachusetts Institute of Technology
    Inventors: Phillip A. Sharp, Qiang Zhou
  • Antisense inhibition of bcl-6 expression
    Patent number: 6140125
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bc1-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bc1-6. Methods of using these compounds for modulation of bc1-6 expression and for treatment of diseases associated with expression of bc1-6 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Deoxynucleic alkyl and alkoxy thiourea compounds
    Patent number: 6136965
    Abstract: The invention provides novel deoxynucleic alkyl thiourea (dNXt) oligonucleotide compounds for use in antisense or antigene therapy.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: October 24, 2000
    Assignee: The Regents of the University of California
    Inventors: Thomas C. Bruice, Dev P. Arya
  • Antisense inhibition of methionine aminopeptidase 2 expression
    Patent number: 6136604
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of methionine aminopeptidase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding methionine aminopeptidase 2. Methods of using these compounds for modulation of methionine aminopeptidase 2 expression and for treatment of diseases associated with expression of methionine aminopeptidase 2 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt